CTI BIOPHARMA CORP

$7.06 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About CTI BIOPHARMA CORP

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Stock Analysis

last close $7.43
1-mo return 18.9%
3-mo return 42.6%
avg daily vol. 3.74M
52-week high 7.8
52-week low 1.43
market cap. $810M
forward pe -
annual div. -
roe -2944%
ltg forecast -
dividend yield -
annual rev. $2M
inst own. 63.4%
baraka

Subscribe now for daily local and international financial news

Subscribe